陆勤超 | Cherry Lu

Founder of Danlu capital & Executive partner

Ms. Lu Qinchao has been engaged in marketing and project cooperation in the medical field for many years. She is an early explorer and practitioner in the industry. She has accumulated rich industry knowledge and experience. She founded Danlu capital in early 2018 and served as an executive partner, focusing on early investment in the medical industry for a long time. Since its establishment, Danlu capital has invested in dozens of medical enterprises, many of which have grown into industry leaders, such as beirelaxed (688793), Kefu medical (301087), liangyihui, etc. they are deeply rooted in the subdivided fields of the medical industry, have great leading advantages in their respective fields, and their innovation ability is at the forefront of the industry.

苏震波 | Frank Su

Founder of Danlu capital & Executive partner

Mr. Su Zhenbo has many years of experience in the medical industry. He once worked in the senior management of many well-known medical multinational enterprises such as Johnson & Johnson. He co founded techlink medical, a surgical product company, and led the company to become one of the leading enterprises in the subdivided field. Since 2013, he has served as the managing partner of Shenzhen shared investment medical fund and directly led the investment of more than 10 medical projects. Most of them entered as the earliest institutional investors. At present, he has grown into a leading enterprise in the subdivided industry, including a number of well-known medical enterprises such as Beijing panshengzi (GTH), Guangzhou Maipu (301033. SZ), Beijing tiankeya and Beijing Houkai.

许谦|Gavin Xu

丹麓合伙人

He has more than 20 years of experience in the investment industry. He once served as a partner of Detong capital and the deputy general manager of Fosun Pharmaceutical investment headquarters. He also served in well-known institutions such as Chinese Academy of Sciences Holdings Co., Ltd. and Tsinghua Xingye Investment Management Co., Ltd. He led the investment in industry-leading projects such as huakan biology, mengke Pharmaceutical (688373), Shulan medical, Donglei brain science, liangyihui, tiankeya biology, Houkai medical, Sinopharm Stomatology, micro medicine group, etc. he served as a director of Chengdu information of Chinese Academy of Sciences, beilai biology and other companies.
Tutor of innovation and entrepreneurship platform X-lab of Tsinghua University; Tutor of Tsinghua Wudaokou global entrepreneurship project; Distinguished researcher of Peking University Medical Information Consulting Center; Editorial board member of progress in pharmacy; Tutor of IBM Global Entrepreneur training camp; Zhongguancun Angel Growth Camp tutor.
He served as the co chairman of China Venture Capital Commission; Executive director of Beijing fund industry association.
EMBA, Wudaokou School of finance, Tsinghua University, master of science, Graduate School, Chinese Academy of Sciences.
Honors and achievements:
2020-2021 arterial network annual health care investor
2019 Zhongguancun high end leading talents (Beijing)
2018 Zhongguancun venture capital star
2015 Fosun Pharmaceutical annual manager Award

李洁|Jack Li

生物医药合伙人

Biomedical partner (Master Fund Research Center (40u40) is the most potential youth investor of direct investment fund
■ Li Jie has many years of medical and health investment experience in investment companies. She used to be the chief medical adviser of Investment Banking Department of Guangfa Securities and the person in charge of Jinshi investment / Guangzheng Venture Capital Medical. She has a broad industry vision and experience in project IPO, industrial merger and investment.
■ doctor of Science / Master of science, Institute of Biophysics, Chinese Academy of Sciences, Bachelor of Biomedical Engineering, Southeast University.